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1. INTRODUCTION
 2 
1.1. Osteoarthritis 
Osteoarthritis is a chronic degenerative disease predominantly affecting weight bearing joints 
in the human body. It is currently suggested to be a heterogeneous disease caused by a 
combination of excessive wear and tear as well as abnormal joint mechanics and inflammation. 
The concept of its pathophysiology is still unfolding. Through progress in molecular biology it 
evolved from being viewed as a cartilage-limited disorder to a multifactorial disease affecting 
the whole joint. This intricate relationship between local and systemic factors modulates its 
structural features and clinical presentation leading to a common final pathway of joint 
destruction [1]. 
The pain underlying Osteoarthritis is of heterogeneous nature. An interplay between local 
pathologic changes, neuroplastic changes as well as general factors like adipositas, diabetes 
mellitus and psychosocial factors have been identified to be responsible for the development of 
chronic joint pain [2]. Presumably arising from mechanical sensitization of joint nociceptors 
through inflammation, pain perception progresses in response to a complex series of 
neurophysiologic events. They are comprised of sensitization of peripheral and central 
pathways as well as reduction of descending conditioning pain modulation and atrophy of 
cortical areas involved in pain processing [2]. Moreover, a subset of patients pain phenotype 
indicates a neuropathic component [3]. All those mechanisms combined likely skew the 
relationship between the extend of tissue injury and perceived pain in any situation but the acute 
one. Current evidence suggests osteoarthritic damage predisposes to pain but there is little 
correlation between the severity of pain and the extend of joint damage [4]. 
 
 
Osteoarthritis most commonly results from a combination of modifiable and non-modifiable 
risk factors including obesity, trauma, increasing age, genetic predisposition and gender. Those 
affected classically suffer from pain, stiffness and limited range of motion ultimately leading 
to joint destruction and the necessity to perform joint replacement surgery [5]. 
Osteoarthritis is the single most common cause of chronic disability in older adults [5]. A report 
from the Global Burden of Disease 2010 study indicated that of the 291 conditions listed, hip 
and knee osteoarthritis was ranked globally as the 11th highest contributor to global disability 
and the 38th highest in disability-adjusted life years (DALYs) [6]. It is estimated that 10-15% 
of all adults aged over 60 have some degree of osteoarthritis with a prevalence that is higher 
among women than men [7] The increasing lifespan of the general population combined with 
an expected rise in obese patients can potentially aggravate the global impact of this disease. 
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According to the United Nations, by 2050, 130 million people will suffer from OA worldwide 
of whom 40 million will be severely disabled by the disease [8] 
Treatment of osteoarthritis is directed at pain alleviation, improvement of physical function and 
the delay of joint replacement surgery. Treatment modalities are generally divided into non-
pharmacological, pharmacological and surgical options. Non-pharmacologic options include: 
patient education, application of heat and cold, weight loss, low to moderate intensity exercise, 
physical therapy and mechanical joint unloading through braces or foot wear [5]. 
Pharmacologic options include medicines such as acetaminophen, topical and oral non-
steroidal anti-inflammatory drugs (NSAIDS), tramadol and intra-articular injections like 
corticosteroids or autologous Plasma. Additionally, there are certain nutritional supplements, 
foremost glucosamine, which has shown some beneficial results in osteoarthritis clinical trials 
[9]. New potential targets for analgesic therapy have been identified. The antibody tanezumab 
targeting nerve growth factor; sensory proteins at the nociceptive nerve endings such as the 
activating TRPV and ASIC channel. Additionally, axonal channels such as voltage-gated 
Sodium channels, various potassium channels as well as inhibitory opioid and cannabinoid 
receptors [10].  
Surgical procedures that are used for symptomatic treatment of osteoarthritis include 
arthroscopy for debridement, osteotomy or fusion [11]. Unfortunately, the only definite 
treatment is joint replacement which, due to limited durability of modern implants, is often 
preceded by years of chronic analgesic use and significant disability. After successful 
arthroplasty, as defined by prosthesis-related outcomes, still a proportion of about 9% of 
patients with hip and about 20% of patients with knee replacements have unfavorable long-
term results with patient-centered pain outcomes over a follow up from 3 month to 5 years after 
surgery [12]. In order to address the time period from onset of disease to joint replacement, 
patients need therapies that provide adequate pain relief over an extended period of time. 
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1.3. Celecoxib 
Celecoxib is a drug belonging to the class of coxibs, recommended for symptomatic treatment 
of osteoarthritis. Like conventional NSAIDS, they work by inhibiting the cyclooxygenase 
enzyme which converts arachidonic acid into prostaglandins which further mediate pain and 
inflammation amongst other functions. The cyclooxygenase enzyme has two isoforms active in 
humans. The constitutive COX-1 is present, for example in the endothelium, stomach and 
kidney, whereas COX-2 is induced by pro-inflammatory cytokines and endotoxin in cells in 
vitro and at inflammatory sites in vivo [13]. In contrast to conventional NSAIDS which inhibit 
both isoforms of the enzyme non-selectively, coxibs are relatively more selective for the COX-
2 enzyme. Whilst equally efficacious their specificity presumably gives them a more favorable 
side effect profile. Unfortunately, this has not been confirmed in the Cochrane review 
“Celecoxib for osteoarthritis” [14]. 
 
1.4. Cochrane systematic review 
Systematic reviews are secondary research projects in which researchers attempts to gather all 
the existing empirical evidence that meets pre-specified eligibility criteria in order to answer a 
specific research question. Methods used for conducting such reviews should be explicit and 
systematic, striving towards minimization of bias in order to facilitate the production of reliable 
findings for further decision making [15]. Those reviews are complicated and their results 
heavily depend on the availability, and even more importantly, the quality of existing clinical 
trials. The strength of the evidence of the systematic review directly correlates with the quality 
of included studies. If possible, in a systematic review authors may pool numerical data about 
treatment effects through the process of meta-analysis. Through this process systematic reviews 
are able to summarize all the existing clinical research concerning a particular research question 
[16]. 
Cochrane systematic reviews are considered gold standard in evidence synthesis field. They 
are produced by Cochrane, a global independent network of health practitioners, researchers, 
patient advocates and people interested in health from over 130 countries. Cochrane has more 
than 37000 contributors that collectively respond to the challenge of making the vast amount 
of evidence available through research applicable for consumers. Cochrane is a not-for profit 
organization whose mission is to produce high quality evidence that is free from commercial 
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sponsorship and other conflicts of interests in order to facilitate evidence-based decision 
making in the health-care setting [17]. 
Cochrane systematic reviews are systematic reviews in the field of health-care published in the 
Cochrane Database of Systematic Reviews (CDSR), the leading journal for systematic reviews 
in health care [18]. Cochrane has developed a meticulous methodological approach for 
producing systematic reviews. There are five types of systematic reviews in CDSR: reviews of 
the effects of interventions, reviews of diagnostic test accuracy, methodology reviews, 
qualitative reviews, and methodology reviews [19]. Additionally, CDSR publishes overviews 
of systematic reviews, i.e. systematic reviews that summarize systematic reviews [20]. All those 
reviews follow a clear structured review model which is provided in the Cochrane Handbook 
for Systematic Reviews of Interventions [21]. Guidance available in the Cochrane Handbook 
should guarantee consistency of methods used in Cochrane reviews.  
 
1.5. Cochrane review about celecoxib for osteoarthritis 
Cochrane review “Celecoxib for osteoarthritis” was published in the CDSR in 2017 [14]. The 
review showed no statistically significant difference between celecoxib and placebo for serious 
adverse effects, gastro-intestinal events (perforations, ulcers bleeds) and cardiovascular events 
(myocardial infarction, stroke). Due to high risk of bias and imprecision it is to be noted that 
evidence level was downgraded to very low quality [14].  
The same review reached several other conclusions relevant for clinical decision making: 
Firstly, they noted that benefits of celecoxib were not much different than placebo or other 
NSAIDS. Furthermore, they noticed decreasing efficacy of celecoxib for pain with longer 
duration of included studies, expressed as decreasing standardized mean difference [14]. 
On the contrary, previous data from the research group of prof. Andrew Moore indicated that 
there is high correlation of pain scores measured with a visual-analog-scale (VAS) after 2 and 
6 weeks of treatment with VAS pain scores at 12 weeks in randomized controlled trials (RCTs) 
about rheumatoid arthritis and osteoarthritis [22]. This group of authors concluded that early 
analgesic response measuring pain scores with VAS beyond 2 weeks of treatment with a 
particular NSAID is likely to be predictive of pain VAS response at 12 weeks, and that these 
results have implications for future study design of randomized controlled trials RCTs). 
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Namely, the authors suggest that appropriate treatment duration for studies of efficacy in this 
setting could be shorter, for example 6 weeks instead of 12 weeks [22]. 
Since efficacy data for pain from the Cochrane review “Celecoxib for Osteoarthritis” would 
imply different conclusion compared to conclusions of Moore and colleagues, the aim of this 
study was to conduct more comprehensive analysis of efficacy data for pain in RCTs about 
celecoxib for osteoarthritis over different follow-up times. 
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2. OBJECTIVES 
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The aim of this Thesis was to conduct more comprehensive analysis of efficacy data for pain 
in RCTs about celecoxib in osteoarthritis. The purpose of this is to improve long-term 
management of pain for patients suffering from osteoarthritis by guiding clinical decision 
making, and to create evidence that will inform design of future RCTs about osteoarthritis. 
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3. METHODS 
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3.1. Study Design 
This was a retrospective primary methodological study, in which publicly available data from 
published RCTs were analyzed. Therefore, permission of the ethics committee for data 
collection was not necessary. 
 
3.2. Inclusion of studies 
We included RCTs analyzing the effects of celecoxib on pain intensity measured with the 
Visual Analog Scale (VAS) and/or the Western Ontario and McMaster University 
Osteoarthritis Index (WOMAC), and comparing celecoxib with placebo. We did not limit 
studies based on duration, and we had no limits regarding language. Search strategy used for 
retrieving eligible studies was described in the Cochrane review “Celecoxib for Osteoarthritis”, 
and we used for this analysis all eligible RCTs that were found in the literature while conducting 
our Cochrane review [14]. 
 
3.3. Types of Intervention 
Oral celecoxib 200 mg daily (either as 200 mg once daily or 100 mg twice daily) versus Placebo. 
Dosage of 200 mg was used because it is the recommended dosage.  
 
3.4. Types of outcome measures 
The outcome measure was pain. Pain scales used were the VAS scale and the WOMAC  
osteoarthritis index pain sub score.  
 
3.5. Extraction of data 
We extracted the following data from eligible RCTs: study ID (first author, year), study 
duration in weeks, follow-up times used in the study for measuring pain intensity, efficacy data 
for pain measured with VAS and/or WOMAC for all reported follow-up times (mean, standard 
deviation, number of participants). If the study reported data only in figures, we extracted data 
from figures using the Plot Digitizer software [23]. We extracted data in the way they were 
presented, including baseline data, final end-of-study data and change from baseline. 
 
3.6. Data analysis 
Since the majority of data were reported as change from baseline, for the studies that reported 
baseline data and absolute values at different time points, we calculated change from baseline 
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using baseline data and time point data using methods recommended in the Cochrane Handbook 
for Systematic Reviews of Interventions [24].  
 
We used random-effects meta-analyses for synthesis of pain scores for different pain outcome 
measures and different follow-up time points that were reported in included studies. 
Standardized mean differences (SMDs) were used to report the data. We used Review Manager 
(RevMan) for data analyses [25]. 
 
3.7. Data imputations 
Missing standard deviations (SDs) were imputed only from baseline data or other follow-up 
data of the same manuscript. We did not do any imputations for missing SDs from other 
manuscripts. For studies that have shown only absolute results, we calculated change from 
baseline. 
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4. RESULTS 
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Included studies 
We included 35 RCTs in this analysis. All included RCTs were published as full-text 
manuscripts. We did not find any eligible RCTs that were published as conference abstracts, or 
that were unpublished. The list of included studies is shown in Table 1. 
 
Table 1. List of included studies  
No Included studies 
1.  Asmus 2014 Study 1 [26] 
2.  Asmus 2014 Study 2 [26] 
3.  Bensen 1999 [27] 
4.  Bingham 2007 Study 1 [28] 
5.  Bingham 2007 Study 2 [28] 
6.  Birbara 2006 Study 1 [29] 
7.  Birbara 2006 Study 2 [29] 
8.  Boswell 2008 Study a [30] 
9.  Boswell 2008 Study b [30] 
10.  Clegg 2006 [31] 
11.  Conaghan 2013 [32] 
12.  De Lemos 2011 [33] 
13.  Essex 2016 [34] 
14.  Fleischmann 2005 [35] 
15.  Gibofsky 2003 [36] 
16.  Gordo 2017 [37] 
17.  Hochberg 2011 Study 307 [38] 
18.  Hochberg 2011 Study 309 [38] 
19.  Kivitz 2001 [39] 
20.  Lee M 2017 [40] 
21.  Lehman 2005 [41] 
22.  Mc Kenna 2001a [42] 
23.  Mc Kenna 2001b [42] 
24.  Pincus 2004 PACES-a [43] 
25.  Pincus 2004 PACES-b [43] 
26.  Reginster 2017 [44] 
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27.  Rother 2007 [45] 
28.  Schnitzer 2011 [46] 
29.  Sheldon 2005 [47] 
30.  Smugar 2006 Study 1 [48] 
31.  Smugar 2006 Study 2 [48] 
32.  Tannenbaum 2004 [49] 
33.  Williams 2000 [50] 
34.  Williams 2001 [51] 
35.  Wittenberg 2006 [52] 
 
We excluded 14 studies due to reasons listed in the Table 2. 
 
Table 2. List of excluded studies   
No Excluded studies Reason for exclusion 
1.  Bianchi 2003 [53] fewer than 50 participants in each arm 
2.  Bianchi 2007 [54] fewer than 50 participants in each arm 
3.  Detrembleur 2005 [55] fewer than 50 participants in each arm 
4.  EUCTR2005-002772-14-GB Outcome data is the same as in Schnitzer 
2011 
5.  EUCTR2011-005398-22-ES Results are not available 
6.  Gallelli 2013 [56] fewer than 50 participants in each arm 
7.  Leeb 2004 [57] fewer than 50 participants in each arm 
8.  Mastbergen 2010 [58] fewer than 50 participants in each arm 
9.  NCT01768520   Results of study could not be found. Stated to 
use Korean WOMAC  
10.  Ozgocmen 2005 [59] fewer than 50 participants in each arm 
11.  Sampalis 2012 [60] fewer than 50 participants in each arm 
12.  Simon 1998 [61] SD not reported, and could not be imputed 
from other results reported in this manuscript 
13.  Tascioglu 2004 [62] fewer than 50 participants in each arm 
14.  Trudeau 2015 [63] fewer than 50 participants in each arm 
 
 15 
Results from the Schnitzer 2011 study and results posted for the study EUCTR2005-002772-
14-GB registered at the International Clinical Trials Registry Platform (ICTRP) had exactly the 
same results, up to two decimals. Even though the Schnitzer 2011 study reported in the 
manuscript that the study was registered only on ClinicalTrials.gov (NCT00154219), details in 
these two registrations on ICTRP and on ClinicalTrials.gov are identical, and therefore we 
considered that these are the same studies, and we did not include these data two times in our 
analysis. 
 
Effect sizes 
Time points for results available for data analysis in included studies that have reported pain 
using VAS are shown in Table 3, while the time points for results in studies that reported pain 
using WOMAC is shown in Table 4. 
 
Table 3. Time points with results for pain measured with visual analogue scale (VAS) in 
included studies 
Time point Study name 
2 weeks  Bensen 1999 
Bingham 2007 study 1 
Bingham 2007 study 2 
Fleischmann 2005 
Kivitz 2001 
Lehman 2005 
McKenna 2001b 
Sheldon 2005 
Simon 1998 
Tannenbaum 2004 
Williams 2000 
Williams 2001 
3 weeks Gibofsky 2003 
 McKenna 2001a 
4 weeks Bingham 2007 study 1 
Bingham 2007 study 2 
Lehman 2005 
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Sheldon 2005 
Schnitzer 2011 
Tannenbaum 2004 
30 days Reginster 2017 
6 weeks Asmus 2014 study 1 
 Asmus 2014 study 2 
 Bensen 1999 
 Essex 2016 
 Gibofsky 2003 
 Gordo 2017 
 Kivitz 2001 
 McKenna 2001b 
 Pincus 2004 PACES-a 
 Pincus 2004 PACES-b 
 Williams 2000 
 Williams 2001 
8 weeks Bingham 2007 study 1 
 Bingham 2007 study 2 
 Lehman 2005 
 Schnitzer 2011 
 Sheldon 2005 
 Tannenbaum 2004 
9 weeks Conaghan 2013 
 DeLemos 2011 
12 weeks Bensen 1999 
 Bingham 2007 study 1 
 Bingham 2007 study 2 
 DeLemos 2011  
 Kivitz 2011 
13 weeks Fleischmann 2005 
 Lehman 2005 
 Reginster 2007 
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Table 4. Time points with results for pain measured with Western Ontario and McMaster 
Universities Osteoarthritis index (WOMAC) in included studies 
Time point Study name 
1 week Boswell 2008 Study A 
 De Lemos 2011  
 Wittenberg 2006 
2 weeks Bensen WG 1999 
 Birbara 2006 Study 1 
 Birbara 2006 Study 2 
 Boswell 2008 Study A 
 Boswell 2008 Study B 
 Conaghan 2013 
 De Lemos 2011 
 Fleischmann 2005 
 Kivitz 2001 
 Lehman 2005 
 Smugar 2006 Study 1 
 Smugar 2006 Study 2 
 Tannenbaum 2004 
3 weeks De Lemos 2011 
 Lee M 2017  
4 weeks Birbara 2006 Study 1 
 Birbara 2006 Study 2 
 Boswell 2008 Study A 
 Boswell 2008 Study B 
 Mastbergen 2010 
 Schnitzer 2011 
 Sheldon 2005 
 Tannenbaum 2004 
14 weeks Pincus 2004 PACES-a 
 Pincus 2004 PACES-b 
15 weeks Fleischmann 2005 
26 weeks Reginster 2017 
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 Schnitzer 2011 
 Smugar 2006 Study 1 
 Smugar 2006 Study 2 
6 weeks Asmus 2014 Study 1 
 Asmus 2014 Study 2 
 Birbara 2006 Study 1  
 Birbara 2006 Study 2 
 Boswell 2008 Study A 
 Conaghan 2013 
 De Lemos 2011 
 Essex 2016 
 Gibofsky 2003 
 Gordo 2017 
 Hochberg 2011 Study 307 
 Hochberg 2011 Study 309 
 Lee M 2017 
 Rother 2007 
 Williams 2000 
 Williams 2001 
8 weeks Boswell 2008 Study B 
 Schnitzer 2011 
9 weeks Conaghan 2013 
 De Lemos 2011 
12 weeks Bensen WG 1999 
 Bingham 2007 Study 1 
 Bingham 2007 Study 2 
 Boswell 2008 Study B 
 Conaghan 2013 
 De Lemos 2011 
 Hochberg 2011 Study 307 
 Hochberg 2011 Study 309 
 Kivitz 2001 
13 weeks Fleischmann 2005 
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 Lehman 2005 
 Schnitzer 2011 
 Sheldon 2005  
 Tannenbaum 2004 
24 weeks Clegg 2006 
 
We imputed SD from other parts of the manuscript in 7 studies (Bensen 1999, Kivitz 2001, 
McKenna2001a, Lehman 2005, Schnitzer 2011, Tannenbaum 2004, De Lemos 2001). There 
were 5 studies that showed only absolute values, and for which we calculated change from 
baseline (Bensen 1999, Gibofsky 2003, Reginster 2007, Williams 2000, Williams 2001). 
We made 20 meta-analyses based on the included studies. There were 2 meta-analyses with 
only one study included. Other meta-analyses had from 2 to 18 included studies. The list of 
meta-analyses conducted is shown in Table 5 and 6 for pain VAS and pain WOMAC 
respectively. 
As shown in Tables 5 and 6, SMDs had decreasing trend from earliest to latest analyzed time 
points, both for VAS and for WOMAC, indicating that the effect of celecoxib as an intervention 
was decreasing with time. However, all these studies were of short duration – the longest 
follow-up time used in studies that reported pain using VAS was 13 weeks, while the longest 
follow-up time reported for WOMAC pain was 24 weeks. 
 
Table 5. Standardized mean difference (SMD) for pain in studies that compared celecoxib 
versus placebo, measured with visual analog scale 
Time 
point 
SMD and 95% CI Heterogeneity Number of 
studies 
Number of 
participants 
2 weeks -0.50 (-0.63 to -0.38) 81% 12 6047 
3 weeks -0.53 (-0.73 to -0.32) 0% 2 408 
4 weeks -0.45 (-0.55 to -0.35) 54% 6 3910 
30 days -0.13 (-0.32 to 0.07) Not applicable 1 399 
6 weeks -0.44 (-0.55 to -0.32) 71% 12 4141 
8 weeks -0.41 (-0.52 to -0.30) 64% 6 3910 
12 weeks -0.48 (-0.64 to-0.31) 66% 5 1822 
13 weeks -0.23 (-0.30 to -0.17) 0% 7 3763 
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Table 6. Standardized mean difference (SMD) for pain in studies that compared celecoxib 
versus placebo, measured with WOMAC scale 
Time 
point 
SMD and 95% CI Heterogeneity Number of 
studies 
Number of 
participants 
1 week -0.32 (-0.46 to - 0.18) 0% 3 828 
2 weeks -0.37 (-0.44 to -0.29) 53% 13 6146 
3 weeks -0.37 (-0.53 to -0.20) 0% 2 618 
4 weeks -0.30 (-0.39 to -0.21) 23% 7 3052 
6 weeks -0.35 (-0.43 to -0.27) 45% 16 5128 
8 weeks -0.29 (-0.49 to -0.08) 63% 2 1165 
9 weeks -0.24 (-0.37 to -0.11) 0 % 2 862 
12 weeks -0.32 (-0.40 to -0.25) 13% 9 3468 
13 weeks -0.27 (-0.33 to -0.20) 0% 5 3393 
24 weeks -0.13 (-0.28 to -0.03) Not applicable 1 631 
 
Forest plots for individual meta-analyses are shown in Figures 1-19. 
 
 
 
Figure 1. Comparison celecoxib versus placebo, outcome: pain VAS, 2 weeks 
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Figure 2. Comparison celecoxib versus placebo, outcome: pain VAS, 3 weeks 
 
 
 
 
 
Figure 3. Comparison celecoxib versus placebo, outcome: pain VAS, 4 weeks 
 
 
 
 
 
Figure 4. Comparison celecoxib versus placebo, outcome: pain VAS, 30 days 
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Figure 6. Comparison celecoxib versus placebo, outcome: pain VAS, 6 weeks 
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Figure 7. Comparison celecoxib versus placebo, outcome: pain VAS, 8 weeks 
 
 
 
 
 
Figure 8. Comparison celecoxib versus placebo, outcome: pain VAS, 12 weeks 
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Figure 9. Comparison celecoxib versus placebo, outcome: pain VAS, 13 weeks 
 
 
 
 
 
Figure 10. Comparison celecoxib versus placebo, outcome: pain WOMAC, 1 week 
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Figure 11. Comparison celecoxib versus placebo, outcome: pain WOMAC, 2 weeks 
 
 
 
 
 
Figure 12. Comparison celecoxib versus placebo, outcome: pain WOMAC, 3 weeks 
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Figure 13. Comparison celecoxib versus placebo, outcome: pain WOMAC, 4 weeks 
 
 
 
 
 
Figure 14. Comparison celecoxib versus placebo, outcome: pain WOMAC, 6 weeks 
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Figure 15. Comparison celecoxib versus placebo, outcome: pain WOMAC, 8 weeks 
 
 
 
 
 
Figure 16. Comparison celecoxib versus placebo, outcome: pain WOMAC, 9 weeks 
 
 
 
 
 
Figure 17. Comparison celecoxib versus placebo, outcome: pain WOMAC, 12 weeks 
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Figure 18. Comparison celecoxib versus placebo, outcome: pain WOMAC, 13 weeks 
 
 
 
 
 
 
Figure 19. Comparison celecoxib versus placebo, outcome: pain WOMAC, 24 weeks 
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5. DISCUSSION 
 
 30 
In this study we found a decreasing trend of a numerical indicator for efficacy of celecoxib for 
treatment of pain in studies that compared celecoxib and placebo, and reported pain results with 
VAS and WOMAC scales. It has to be emphasized that these studies were relatively short, 
considering the chronic nature of osteoarthritis; the longest follow-up in the group of studies 
that reported VAS pain was 13 weeks and those that reported WOMAC pain was 24 weeks. 
There was only one study for data analysis for the domain WOMAC at 24 weeks. Additionally, 
SMD remained fairly constant with VAS over most follow up times (SMD at 2 weeks: -0.50; 
SMD at 12 weeks: -0.48) as well as with WOMAC (SMD at 2 weeks: -0.32; SMD at 12 weeks: 
-0.32). The later follow-up times showed a decreased SMD for VAS at 13 weeks (SMD: -0.23) 
and for WOMAC at 24 weeks (SMD: -0.13). 
 
This study was conducted because we observed discrepancies between the 2017 Cochrane 
review on celecoxib for osteoarthritis and results published by Moore et al. [22]. Moore et al. 
used regression models to assess correlation between efficacy comparing diclofenac, ibuprofen, 
naproxen, celecoxib or etericoxib with each other or with placebo at 2, 6 and 12 weeks. Their 
evidence base consisted of 50 RCTs used for analysis. The results suggested that average 
change from baseline (CFB) of VAS pain at all time-points were highly associated. Therefore, 
pain VAS at 2 weeks was predictive of pain VAS at 6 and 12 weeks [22]. Similar predictive 
effects of early response to NSAIDs in predicting late response where demonstrated earlier by 
Bingham et al. in a pooled analysis of 2 identical 26-week studies testing etericoxib, celecoxib 
and placebo in patients with OA of the hip and knee. With active treatment 75% of patients 
who were responders at 2 weeks were also responders at 12 weeks [64]. Both groups analyzed 
follow-up times up to 12 weeks. 
Moore et al. concluded that clinical trials for efficacy of NSAIDs can be shorter as early 
response is likely associated with late response and early treatment failure is likely to be 
associated with treatment failure in general [22]. 
In line with studies of Moore et al. and Bingham et al. this study showed that SMDs observed 
at 2, 6 and 12 weeks remained relatively constant, for pain measured with both VAS and 
WOMAC. 
However, our data also indicate that efficacy of celecoxib measured with pain VAS decreased 
from week 2 (SMD: -0.50) to weeks 13 (SMD: -0.23), as well as with pain WOMAC from 
week 2 (SMD: -0.32) to week 24 (SMD: -0.13).  
Based on our findings, we can provide suggestions concerning future designs of RCTs as well 
as clinical decision-making that are contrary to conclusions of Moore et al. and Bingham et al. 
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Our results indicate that trialists should conduct studies with longer follow-up times in order to 
adequately assess efficacy of celecoxib over a prolonged period. In a chronic condition such as 
OA, for which patient will require adequate analgesic treatment over extended periods, it could 
be misleading to conduct studies with short follow-up times. The overwhelming majority of the 
studies included in our analysis was conducted within 13 weeks, with only one that had 24-
week follow-up and none longer than that. 
Most patients with OA are treated with analgesics for far longer periods than this and a potential 
decrease in efficacy of celecoxib with longer treatment duration has to be addressed due to the 
multiple reasons: 
 
Firstly, inadequate pain relief (IPR) could lead to amplification of pain response through 
maladaptive neuroplastic mechanisms [65]. Secondly, pain is not merely a symptom but also a 
disease on its own which can manifest with chronic pain leading to significant morbidity and 
health care related costs [66]. Additionally, almost one half of all patients are dissatisfied with 
the control of OA pain provided by NSAID therapy, according to a study by Taylor-Stokes et 
al. from 2013 [67]. In a 2014 prospective multinational longitudinal study about real-world 
therapies for OA, it was shown that inadequate pain relief is a highly relevant problem among 
patients with OA. Predictors for IPR included, female sex, higher body mass index (BMI), 
longer OA duration, bilateral knee OA, depression and diabetes. IPR was associated with 
functional loss and impaired quality of life [68].  Furthermore, patients with OA presumably 
prefer medication with a longer treatment effect. This was shown in a study conducted by 
Oxford University and published in April 2019. Researchers conducted a discrete choice 
experiment with 300 residents of the United Kingdom with hip and/or knee OA to quantify 
patients’ preferences for the duration of treatment effect relative to treatment benefits and risks. 
Results showed that pain, severity and duration of treatment effect had the greatest influence 
on medication preference. This suggests that patients would be willing to take medication which 
is less effective in relieving pain if the effect of the medication lasts longer. Moreover, 
participants were willing to accept an increase in the risk of heart attack of 2.6% to increase the 
duration of the treatment effect from one to 12 month [69].  Similar to results of our study, the 
authors appealed to future trialists to conduct clinical trials with longer follow-up for 
investigating treatment effect to evaluate if significant benefit is sustained over time. Duration 
of treatment effect seems to be an important factor in the medication choices of people with 
osteoarthritis and therefore should not be dismissed by researchers and physicians.  
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All in all, it remains unclear how effective NSAIDs are in the treatment of chronic conditions 
such as OA. It was shown in the 2017 review about celecoxib for osteoarthritis that celecoxib 
proved only to be negligibly better than placebo. Results from this review suggest that the 
effectiveness of celecoxib could decrease with treatment duration above 12 weeks. 
We appeal to researchers to conduct additional RCTs with longer follow-up times to address 
this issue. Stratification of patients according to known risk factors for IPR could be helpful in 
further studies. 
 
Joint pain is complex and yet to be understood thoroughly, especially when chronic. A multi-
disciplinary approach in management is crucial in order to provide adequate treatment and 
improved quality of life. 
  
There remains a compelling need for effective, well-tolerated analgesic drugs in order to limit 
inadequate therapy for patients with conditions that can lead to the development of chronic pain 
and all its associated sequelae. There have been significant advances in our understanding of 
the neurobiology of joint pain in OA. Potentially new targets for novel analgesics have been 
identified [10]. 
 
In addition to clarifying the effectiveness of traditionally used drugs like NSAIDs and coxibs, 
future research should focus on novel analgesics in order to bridge the gap between our 
understanding of pain and clinical practice.  
 
Our study had several limitations. We used studies identified in the 2017 Cochrane review, as 
well as additional studies, but we did not systematically search for all potentially newly 
published studies. However, despite this lack of additional systematic search, we are not aware 
of any new studies that have studied efficacy of celecoxib vs. placebo with longer follow-up 
times than reported in this study. As already indicated in the 2017 Cochrane review about 
celecoxib for osteoarthritis, included studies had major limitations and evidence quality was 
poor. Therefore, results should be interpreted with caution. None of the studies in that Cochrane 
review had low risk of bias for all seven assessed domains. Selection bias was poorly reported 
in most trials and attrition bias was high in most trials. Additionally, there was selective 
reporting in about one third of trials.  
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We did not assess risk of bias in additional studies used in this analysis. Another limitation is 
that there was only one study available for the analysis of WOMAC at 24 weeks as well as for 
VAS at 30 days.  
 
Due to involvement of industry sponsors in most of the analyzed trials there is a reason to be 
reserved because it has been shown that such sponsorship may lead to more favorable results 
of the intervention. Cochrane review of Lundh et al. included 75 studies that have analyzed 
whether industry sponsored drug and medical device studies have more favorable results 
compared to studies without such sponsorship and they found that there is an industry bias 
which cannot be explained by standard risk of bias assessment. [70] 
 
Patients in most studies included in the Cochrane review on celecoxib for OA were allowed to 
use rescue medication in case the study medication did not provide adequate pain relieve. This 
is of course necessary from an ethical standpoint, but concerning adequacy of comparative 
results this represents a confounding factor. Trialists did not measure amount of rescue 
medication used by patients and did not include this factor in their analyses of drug efficacy.  
 
Some studies had to be excluded from this analysis because they did not report standard 
deviation or standard error with their main effect. Additionally, we had trouble obtaining 
complete data from certain studies as it was not provided in the published study and further 
requests to study sponsors were not successful. Study authors and sponsors should provide open 
access to their full data sets in order to make use of complete data sets for future analysis. 
Furthermore, in trials with multiple follow-up time points, the trialists should not report only 
results for the final follow-up, but also for all measured follow-ups. Lastly, pain experience in 
OA patients is complex and potentially not measured adequately by existing measures which 
are used in current analysis.  
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6. CONCLUSION 
 35 
 
 
1. It remains unclear how effective celecoxib 200 mg is in comparison to placebo for the 
treatment of osteoarthritis. 
 
2. Our data indicates that efficacy of celecoxib 200 mg could decrease over longer 
follow-up times due to decreasing SMDs found at 13 weeks for VAS and at 24 weeks 
for WOMAC pain scales. 
 
3. Previous research showed a similar trend of efficacy for celecoxib over 12 weeks 
follow-up. Data from later time points used in our study suggest a decrease of efficacy 
with longer follow-up times. 
 
4. Current research about use of celecoxib in osteoarthritis is potentially insufficient for 
patient groups taking Celecoxib for a prolonged period of time. 
 
5. Osteoarthritis is a complex disease with significant socio-economic burden. In order to 
optimize treatment and reduce disease related negative health outcomes new treatment 
modalities are needed that bridge the gap between our understanding of Osteoarthritis 
pain and clinical practice. 
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7. SUMMARY 
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Objectives: The aim of this Thesis was to conduct comprehensive analysis of efficacy data for 
pain in randomized controlled trial RCTs about Celecoxib in osteoarthritis (OA). The ultimate 
purpose of this study is to improve long-term management of pain for patients suffering from 
OA by guiding clinical decision making, and to create evidence that will inform design of future 
RCTs about OA. 
 
Material and Methods: This was a methodological study in which publicly available data from 
RCTs were analyzed. RCTs analyzing the effects of 200 mg celecoxib vs. placebo on pain 
intensity with the Visual Analog Scale (VAS) and Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) score were included. Random effect meta-analysis was used 
for different pain outcome measures and different follow-up times. Standardized mean 
differences were used to report the data. 
 
Results: We found a decreasing trend of a numerical indicator for efficacy of celecoxib for 
treatment of pain in RCTs comparing Celecoxib 200 mg to Placebo and reported pain results 
with the VAS and WOMAC scale. Standardized mean differences remained relatively constant 
with VAS and WOMAC over most follow-up times. The later follow-up times showed a 
decreased SMD for VAS at 13 weeks as well as for WOMAC with 24 weeks.  
 
Conclusion: Our data indicates that efficacy of celecoxib 200 mg could decrease over longer 
follow-up times. Future trials should include assessment at longer follow-up times for adequate 
assessment of efficacy and safety of celecoxib. 
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8. CROATIAN SUMMARY 
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Naslov na hrvatskom jeziku: Promjene intenziteta boli u različitim vremenima praćenja u 
randomiziranim kontroliranim pokusima o celekoksibu za osteoartritis 
Ciljevi: Cilj ove disertacije bio je provesti detaljnu analizu o ishodima koji opisuju intenzitet 
boli u randomiziranim kontroliranim pokusima (engl. randomized controlled trials; RCTs) o 
celekoksibu za osteoartritis (OA). Konačni cilj je dati nove informacije za praksu i omogućiti 
ustroj boljih RCT-ova u budućnosti. 
Metode: Provedeno je metodološko istraživanje u kojem su analizirani javno dostupni podatci 
iz RCT-ova. Uključeni su RCT-ovi koji su analizirali djelotvornost i sigurnost celekoksiba 
200 mg u usporedbi s placebom. Intenzitet boli je analiziran vizualno-analognom ljestvicom 
(engl. Visual-Analog Scale; VAS) i WOMAC ljestvicom (engl. Western Ontario and 
McMaster Universities Osteoarthritis Index). Provedena je meta-analiza nasumičnih učinaka 
(engl. random effect meta-analysis) kako bi se analizirao zbirni učinak za različite mjere 
ishoda u različitim vremenima praćenja. Standardizirane srednje razlike (engl. standardized 
mean differences; SMD) su korištene za prikaz podataka. 
Rezultati: Uočen je trend smanjenja SMD za djelotvornost celekoksiba za liječenje OA 
prema mjernim instrumentima VAS i WOMAC u kasnijim vremenima praćenja. Pokusi koji 
su koristili ljestvicu VAS trajali su najviše 13 tjedana, a pokusi koji su koristili ljestvicu 
WOMAC najviše 24 tjedna. 
Zaključak: Dobiveni podatci ukazuju da bi djelotvornost celekoksiba za liječenje boli u OA 
mogla biti manja s duljim vremenom primjene lijeka. Novi klinički pokusi trebali bi uključiti 
dulje vrijeme praćenja kako bi se dobili odgovarajući podatci iz istraživanja o dugoročnoj 
djelotvornosti i sigurnosti celekoksiba u OA koji je kronična bolest 
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